C 101

Drug Profile

C 101

Alternative Names: C-101; Myodur

Latest Information Update: 27 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CepTor Corporation
  • Class
  • Mechanism of Action Calpain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Muscular dystrophies

Highest Development Phases

  • Discontinued Muscular dystrophies

Most Recent Events

  • 11 Sep 2006 CepTor has filed an IND Complete Response with the FDA in the USA for Duchenne muscular dystrophy
  • 25 Apr 2006 Preclinical data from a media release have been added to the Musculoskeletal disorders pharmacodynamics section
  • 25 Jan 2006 C 101 has received Orphan Drug Status for Duchenne's and Becker muscular dystrophies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top